|Bid||9.81 x 800|
|Ask||9.94 x 1400|
|Day's Range||9.63 - 10.15|
|52 Week Range||7.01 - 30.99|
|Beta (5Y Monthly)||-1.97|
|PE Ratio (TTM)||5.69|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The roller-coaster-like trajectory that has been Co-Diagnostics' (NASDAQ: CODX) stock price climbed another hill on Thursday. Co-Diagnostics announced that its CoPrimer diagnostics platform, which underpins testing products -- like its popular-for-obvious-reasons Logix Smart for COVID-19 -- has been granted a patent in South Korea. "We believe that this patent granted by South Korea provides additional validation of the uniqueness and versatility of the CoPrimer platform," the company quoted CEO Dwight Egan as saying.
In this article we will analyze whether Co-Diagnostics, Inc. (NASDAQ:CODX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead into […]
It's been a good week for Co-Diagnostics, Inc. ( NASDAQ:CODX ) shareholders, because the company has just released its...